Company news
Dimerix Limited news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Chair address and CEO presentation to AGM
November 28, 2022
Dimerix Receives A$6.0M R&D Tax Incentive Rebate
October 24, 2022
Appendix 4E and 2022 Annual Report
August 28, 2022
CLARITY 2.0 COVID-19 Study Concludes Recruitment
August 17, 2022
New Patent Family Application for DMX-700
August 8, 2022
DMX-700 Study Shows Significant 80% Reduction in Lung Injury
July 3, 2022
REMAP-CAP COVID-19 Study Analysis Update
June 26, 2022
New Clinical Trial for DMX-200 in Diabetic Kidney Disease
June 6, 2022
Phase 3 FSGS Kidney Trial First Patient Recruited
May 30, 2022
Dimerix presentation at Bioshares Biotech Summit
May 11, 2022
FDA IND Approval for Phase 3 Study of DMX-200 in FSGS
May 8, 2022
Dimerix Receives A$3.7M R&D Tax Incentive Rebate
March 28, 2022
DSMB Change to REMAP-CAP COVID-19 Study
February 27, 2022
Half-Year Financial Report & Appendix 4D - 31 December 2021
February 23, 2022
First Regulatory Approval in Europe for DMX-200 FSGS Study
February 1, 2022
Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India
January 10, 2022
Ethics Approval in Australia for Phase 3 COVID-19 Study
December 22, 2021
DSMB Recommends Continuation of Ph3 COVID-19 Study in Europe
December 16, 2021
Pause in Trading
December 15, 2021
First Approvals Received for Start of Phase 3 FSGS Trial
October 20, 2021
Phase 3 DMX-200 COVID-19 Study Expands into Australia
October 14, 2021
Dimerix Closes SPP Oversubscribed
September 30, 2021
DMX-200 CLARITY COVID-19 Study Approval in India
September 24, 2021
Phase 3 Study in FSGS Kidney Patients Commences
August 24, 2021
SPP and Options Prospectus
August 23, 2021
Response to ASX Query
August 19, 2021
Successful $20m Placement to Fund Phase 3 Trials
August 15, 2021
DMX-200 COVID-19 Study Opens More Sites in Europe and UK
August 1, 2021
FDA Confirms Phase 3 Study Design in FSGS Kidney Disease
July 18, 2021
Dimerix Receives Innovation Passport and ILAP Designation
June 6, 2021
Dimerix Confirms Phase 3 FSGS Study Design With EMA
June 3, 2021
DMX-200 Remains Eligible for Accelerated Approval
May 27, 2021
COVID-19 Study Recruits Multiple Patients in Europe
April 22, 2021
Major Shareholder Loan for $5 Million
March 29, 2021
Clinical Study in Patients with COVID-19 Progresses
March 24, 2021
DMX-200 Competitive Position Further Enhanced
March 23, 2021
CLARITY 2.0 Study Progresses In Patients With COVID-19
March 9, 2021
Appendix 4D and Interim Financial Report
February 21, 2021
Dimerix Plans for Next Study in Diabetic Kidney Disease
January 27, 2021
Second Study to Include DMX-200 in COVID-19 Patients
November 29, 2020
ARDS in COVID-19 Patients Protocol Published
November 8, 2020
Positive Additional Data to Support DMX-200 Development
October 26, 2020
Receipt of R&D Tax Incentive
October 20, 2020
DMX-700 Data Demonstrates Effect on Key COPD Receptors
October 6, 2020
Positive Top-Line Results in DKD Phase 2 Clinical Study
September 13, 2020
Dimerix Awarded $1 Million MRFF Funding
September 2, 2020
Positive Top-Line Results in FSGS Phase 2a Clinical Study
July 28, 2020
Last Patient Completes Dosing in DKD Phase 2 Clinical Study
July 23, 2020
Dimerix Completes $5.8m Placement
June 22, 2020
Last Patient Completes Dosing in FSGS Phase 2 Clinical Study
June 16, 2020
Decks
The 5 newest of 86 decks. Every deck is listed under its year.
- Technical Presentation (October 2026)
Technical · 17 slides · Oct 23, 2026
- Canaccord Genuity Drug and Device Conference 2026
Conference · 35 slides · Oct 12, 2026
- ASX SMIDcaps Conference 2026
Conference · 16 slides · Sep 23, 2026
- E&P Healthcare Conference 2026
Conference · 22 slides · Sep 16, 2026
- Investor Presentation (September 2026)
Investor deck · 35 slides · Sep 7, 2026